Last reviewed · How we verify
NCT06332976: PRACTICE
PrefeRences And ChemoTherapy In Breast Cancer patiEnts
trial testing Completion of questionnaires in Female Breast Cancer in 450 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | European Institute of Oncology |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 450 |
| Start date | 4 June 2021 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Completion of questionnaires
Conditions studied
- Female Breast Cancer — all drugs for Female Breast Cancer →
Sponsor
European Institute of Oncology
Who can join
18 and older, female only, with Female Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the present study is to ask women treated with adjuvant or neoadjuvant chemotherapy for breast cancer what survival benefit would justify the treatment. The benefit should be evaluated in terms of Survival rate trade off and Survival time trade off value. The analyses will be conducted into three different groups of patients to value the survival benefit expected: 1. before to start the chemotherapy 2. during chemotherapy 3. after the end of chemotherapy
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06332976
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Completion of questionnaires
Trials testing the same drug.
- NCT04966091 — Working IVF Patients' Quality of Life · completed
- NCT03939156 — Patients' Preferences for Adjuvant Endocrine Therapy in Early Breast Cancer · unknown
Other recruiting trials for Female Breast Cancer
Currently open trials in the same condition.
- NCT06696378 — Melatonin Supplementation and Exercise Program in Breast Cancer Women · NA · recruiting
- NCT06618690 — Exercise Program on Pain, Physical Function, and Quality of Life in Breast Cancer Survivors · NA · active not recruiting
- NCT06144164 — A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With B · Phase 3 · recruiting
- NCT05586256 — Ultra-hypofractionated Radiotherapy in Breast Cancer Patients · recruiting
Other European Institute of Oncology trials
Trials by the same sponsor.
- NCT07374809 — IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER · NA · not yet recruiting
- NCT07429851 — CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors · recruiting
- NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
- NCT07508319 — Role of the Immune System in Preventing Laryngeal Cancer · recruiting
- NCT07180693 — Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors: · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06332976 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by European Institute of Oncology
- Last refreshed: 27 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06332976.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing